Clinical Updates in Psoriatic Arthritis

The Rheumatology Network psoriatic arthritis clinical focus page provides information on the latest psoriatic arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for psoriatic arthritis drugs.

Alexis Ogdie, MD: Importance of Patient Experience in Psoriatic Arthritis Treatment

June 14, 2021

In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.

Risankizumab Significantly More Effective Than Placebo in Treating Psoriatic Arthritis

June 10, 2021

Risankizumab showed significantly greater improvements in symptoms of psoriatic arthritis when compared with a placebo and was well tolerated in patients who were intolerant to biologics and conventional synthetic disease-modifying antirheumatic drugs.

Alyssa Johnsen, MD, PhD: Guselkumab Improves Joint Symptoms and Skin Clearance in Psoriatic Arthritis

June 08, 2021

Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.

Swollen Joint Count Questioned in Moderate, Oligoarticular Psoriatic Arthritis

June 07, 2021

In addition to swollen joint count, joint location and functional impairment should also be considered when describing psoriatic arthritis as moderate.

Rheumatology Network's Top 5: June 4, 2021

June 04, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 4, 2021.

Improved Psoriatic Arthritis Outcomes in Phase 3b Guselkumab Trial

June 03, 2021

Data from the COSMOS study showed that 44.4% of patients who received guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24.

Laura Coates, MBChB, MRCP, PhD: What Factors Influence Patients' Opinion of Remission?

May 31, 2021

Rheumatology Network interviewed Laura Coates, MBChB, MRCP, PhD, to discuss what her recent study adds to existing psoriatic arthritis (PsA) research, what some of the key factors are that impact a patient’s opinion of remission, and the clinical significance.